Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease.
Predominantly inflammation driven diseases like acute lung injury, asthma, Crohn’s Disease, Ulcerative Colitis and Graft vs Host Disease (GvHD) impact a large and diverse patient population and present a major opportunity for innovation in drug discovery. In this webinar, Drs. Andrew Borkowski and Nicole Smith discuss preclinical models, including models of Inflammatory Bowel Disease (IBD)/colitis, GvHD, and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.
Key Topics Include:
- Learn about translational and predictive animal models of Inflammatory Bowel Disease (IBD), Graft versus Host Disease (GVHD), and pulmonary disease
- Understand the basic components of a successful and comprehensive study design in these therapeutic areas
- Review the typical disease induction approach, disease kinetics, responses to standard of care therapies, and standard endpoints/outcomes that are assessed in these models
- Understand how you can work with BioModels to support your drug development efforts using either established disease models or validating new models and endpoints
- Categories: Drug Discovery & Development, Microbiology & Immunology, Respiratory Science
- Tags: animal model development, animal models, asthma, colitis, graft vs host disease, GVHD, IBS, inflammatory disease, irritable bowel syndrome, lung disease, pulmonary disease
Presenters
Andrew Borkowski, PhD
Principal Scientist
Biomodels
Dr. Borkowski joined Biomodels in 2017 and has diverse interests in the field of immunology and currently works on inflammatory, fibrotic, and pulmonary disease models.
Nicole Smith, PhD
Senior Scientist II
Biomodels
Dr. Smith joined Biomodels in 2017 and is interested in model development and diverse pre-clinical indications, currently focusing on IBD, arthritis, and mucositis.
Production Partner
Biomodels, LLC
Biomodels, is an AAALAC accredited preclinical CRO that develops and executes predictive and highly translational efficacy studies for biotech and pharma companies in a variety of indications. We understand the importance of providing personalized service, innovative solutions and clinically relevant disease models.
Additional Content From Scientist.com
Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials
Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Related Content
Applications of Human Intestinal Organoid Cultures in Drug Discovery
Join STEMCELL TEchnologies' experts as they discuss the use of human intestinal organoid cultures in drug discovery and toxicity testing.
Next-Generation Safety Assessment Tools for Advancing In Vivo to In Vitro Translation
In this webinar, Dr. Louis Scott discusses the morph_ONE™ assay, a novel tool for in vitro safety assessment in drug development.
Organoid Meets Microelectrode Array (MEA) – Accelerating Drug Discovery and Development
In this webinar, Dr. Sven Schönecker and Sara Mirsadeghi, MSc, will discuss 3D Mesh Microelectrode Arrays (MEA) including new developments and applications.
